abstract |
The present invention relates to (2S, 3R, 4R, 5S, 6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6 -(Hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol L-proline and citric acid co-crystals, pharmaceutical compositions comprising said co-crystals, and their role in the treatment of glucose-related Uses in disorders such as type 2 diabetes and syndrome X. |